Over‐expression of the MDM2 gene is found in some cases of haematological malignancies
- 1 October 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 88 (2) , 415-418
- https://doi.org/10.1111/j.1365-2141.1994.tb05044.x
Abstract
We looked for MDM2 gene amplification and over-expression by Southern and Northern blot analysis in 135 and 66 cases of haematological malignancies, including ALL, AML, CML in chronic phase, CLL, MDS, PLL, non-Hodgkin's lymphoma (NHL) and myeloma. No amplification of the gene was found. An over-expression of MDM2 RNA was seen in 9/66 (14%) patients tested, including 3/9 ALL, 3/24 AML, 2/4 myelomas, 1/1 PLL, but 0/2 CML, 0/2 NHL and 0/21 MDS. None of the patients over-expressing MDM2 had modifications of P53 gene transcript or p53 mutations. Most of the patients over-expressing MDM2 gene had poor prognostic features (including 'unfavourable' cytogenetic abnormalities), poor response to chemotherapy and short survival. Our findings suggest that over-expression of MDM2 is seen in a relatively small number of haematological malignancies, and is associated with poor prognosis.Keywords
This publication has 7 references indexed in Scilit:
- Lack of MDM2 amplification in human leukaemiaBritish Journal of Haematology, 1994
- p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expressionBlood, 1993
- The human MDM-2 oncogene is overexpressed in leukemiasBlood, 1993
- Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- P53 gene mutations in acute myeloid leukemia with 17p monosomyBlood, 1991
- p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences, 1991